股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 長江生命科技集團有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00775 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 15,000,000,000 | | HKD | | 0.1 HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | FF301 II. 已發 ...

Financial Performance - For the six months ended June 30, 2025, the company recorded an unaudited loss attributable to shareholders of approximately HKD 150.8 million, compared to a profit of HKD 1 million in the same period last year, representing a negative variance of HKD 151.8 million[13]. - The group reported a revenue of HKD 2,605.8 million for the six months ended June 30, 2025, a decrease of 1.1% compared to HKD 2,635.9 million in the same period of 2024[46]. - The group incurred a loss of HKD 150.8 million for the six months ended June 30, 2025, compared to a profit of HKD 1.0 million in the same period of 2024[46]. - Total revenue for the six months ended June 30, 2025, was HKD 2,605.8 million, a slight decrease of 1.0% from HKD 2,635.9 million in 2024[57]. - Operating cash flow for the six months ended June 30, 2025, was a net outflow of HKD 6.1 million, a significant decrease from a net inflow of HKD 145.4 million in 2024[54]. - The company reported an increase in cash and cash equivalents to HKD 791.1 million as of June 30, 2025, compared to HKD 549.2 million at the end of the same period in 2024[54]. - The group’s financial expenses for the six months ended June 30, 2025, were HKD 143.3 million, a decrease from HKD 169.5 million in the same period of 2024[46]. - The company incurred a tax expense of HKD 15.98 million for the six months ended June 30, 2025, compared to HKD 3.99 million in 2024[60]. - The basic loss per share for the six months ended June 30, 2025, was HKD 0.0157, compared to earnings per share of HKD 0.0001 in 2024[62]. Research and Development - The increase in research and development investment was significant, rising from HKD 72.9 million in 2024 to HKD 235.3 million in 2025, an increase of HKD 162.4 million[13]. - Research and development expenditures amounted to approximately HKD 235.3 million during the reporting period[42]. - The company is in the late-stage development of the cancer vaccine seviprotimut-L, which is currently being tested as an adjuvant therapy for melanoma patients post-surgery[17]. - The company is expanding its innovative therapeutic cancer vaccine combinations targeting various tumor-associated antigens, with promising laboratory results presented at the AACR annual meeting[18]. - The company is utilizing AI to drive the exploration and development of new cancer vaccines, showcasing progress at the AACR annual meeting[19]. - The company plans to continue investing in biotech research and development, acknowledging the high-risk, high-reward nature of the industry[24]. - The company is focused on early cancer detection through liquid biopsy tests, utilizing AI technology for precise predictions[21]. Dividends and Shareholder Returns - The company announced no interim dividend for the 2025 fiscal year, consistent with the previous year[15]. - The company did not declare an interim dividend for the six months ended June 30, 2025, consistent with the previous year[63]. Business Segments Performance - The healthcare products business reported a profit increase of 3% to HKD 160.5 million, compared to HKD 156.4 million last year[22]. - Vitaquest successfully launched new products in the first half of 2025, despite challenging market conditions, and managed to attract new customers[22]. - The agricultural business reported a profit of HKD 130.1 million, slightly down from HKD 134 million last year, primarily due to rising costs and price pressures[23]. - The Australian salt business experienced good growth in both sales and profits, attributed to effective operational strategies and price management[23]. - The vineyard business provided stable profits and cash flow during the review period, benefiting from long-term leases with reputable winemakers[23]. - The agricultural-related business generated revenue of HKD 891.6 million, up 2.9% from HKD 869.6 million in 2024, while the health products business saw a decline to HKD 1,636.7 million from HKD 1,680.8 million[57]. Corporate Governance - The company has adhered to the corporate governance code as per the Hong Kong Stock Exchange's listing rules, ensuring compliance with all applicable provisions[82]. - The board of directors is responsible for establishing and monitoring corporate culture, setting long-term strategic goals, and ensuring effective communication with shareholders[83]. - The company has implemented various governance policies, including anti-fraud, anti-bribery, and whistleblowing policies, to maintain accountability and ethical standards[82]. - The board consists of 11 members, including 6 executive directors and 4 independent non-executive directors, ensuring over one-third of the board is independent[84]. - The chairman and CEO roles are held by different individuals, with the chairman responsible for overall strategic direction and oversight[84]. - The company has established a code of conduct for directors' securities trading, ensuring compliance with the listing rules[86]. - The internal audit department reviews the effectiveness of the group's risk management and internal control systems, providing constructive recommendations[87]. - The audit committee, composed entirely of independent non-executive directors, oversees the financial reporting system and risk management[88]. - The remuneration committee advises on the compensation policies for all directors and senior management[90]. - The nomination committee reviews the board's structure and composition at least annually, ensuring diversity and effectiveness[91]. - The sustainability committee monitors the management of the group's sustainability measures and provides recommendations to the board[92]. - The company maintains effective communication with shareholders and stakeholders, promoting good corporate governance practices[85]. Economic and Market Conditions - The overall economic outlook remains unstable due to geopolitical uncertainties, but the company is confident in strengthening its operational foundation[24]. - The global economic growth continues to slow, potentially leading to market contractions and increased volatility[98]. - The labor market is experiencing significant structural changes, with high employee turnover posing challenges for recruitment and training[99]. - Supply chain disruptions due to geopolitical tensions have led to rising costs and unpredictable delivery times[100]. - The company faces intense competition and rapid technological changes in its operating markets, which may adversely affect its business performance[101]. - Industry trends, including market conditions and interest rate cycles, may pose significant risks to the company's financial performance[105]. - The group faces potential financial impacts due to high interest rates, which may increase financial costs and affect overall business performance[106]. - The group's liquidity is dependent on the successful renewal or refinancing of bank loans and other funding sources[107]. - Currency fluctuations could adversely impact the group's financial condition and potential income, as subsidiaries may operate in different currencies[109]. - Economic sanctions affecting business partners, suppliers, or customers may disrupt operations and lead to financial losses[113]. - Compliance with local, national, and international regulations may impose additional operational costs and risks to the group's business performance[114]. Risks and Challenges - Research and development efforts require substantial resources and time, with no guarantee of positive outcomes from trials[102]. - The ability to attract and retain qualified research personnel is critical for the company's success in product commercialization[103]. - The company's success partly depends on obtaining and enforcing patent rights, with uncertainties regarding the scope and validity of such patents[104]. - Asset impairment risks may affect the group's performance, as any decline in recoverable value below book value must be recognized in the profit and loss statement[108]. - Cybersecurity risks are increasing due to the rapid expansion of technology, which may significantly impact the group's operations and reputation[111]. - The group operates through non-wholly owned subsidiaries and joint ventures, and any changes in partnerships could affect business strategies and performance[112]. - Climate change poses risks to the group's assets and operations, affecting demand, supply, quality, and pricing of products, particularly in agriculture[122]. - The group acknowledges the potential for future public health emergencies, which could negatively impact business operations and financial performance[125]. - Historical performance does not guarantee future results, and actual performance may differ significantly from forward-looking statements due to various risks and uncertainties[126].

Core Insights - Changjiang Life Science Technology (00775) reported a revenue of HKD 2.606 billion for the first half of 2025, representing a year-on-year decrease of 1.14% [1] - The company recorded a loss attributable to shareholders of HKD 150 million, compared to a profit of HKD 1.001 million in the same period last year [1] - The loss per share was HKD 0.0157 [1] Financial Performance - Revenue for the first half of 2025 was HKD 2.606 billion, down from the previous year [1] - The company shifted from profit to loss, primarily due to an increase in research and development investment [1] - R&D expenses rose significantly from HKD 72.9 million in 2024 to HKD 235.3 million in 2025, an increase of HKD 162.4 million [1]

Core Viewpoint - Changjiang Life Science Technology (00775) reported a revenue of HKD 2.606 billion for the first half of 2025, representing a year-on-year decrease of 1.14% [1] - The company recorded a loss attributable to shareholders of HKD 150 million, compared to a profit of HKD 1.001 million in the same period last year, resulting in a loss per share of HKD 0.0157 [1] Financial Performance - Revenue for the first half of 2025 was HKD 2.606 billion, down 1.14% from the previous year [1] - The company experienced a shift from profit to loss, with a loss of HKD 150 million compared to a profit of HKD 1.001 million in the same period last year [1] - Loss per share was reported at HKD 0.0157 [1] Research and Development Investment - The company increased its R&D investment from HKD 72.9 million in 2024 to HKD 235.3 million in 2025, an increase of HKD 162.4 million [1] - This increase in R&D spending is aimed at accelerating the company's research projects [1]

(於開曼群島註冊成立之有限公司) (股份代號：0775) 二零二五年中期業績 二零二五年中期業績 - 增加研發投資 截至二零二五年六月三十日止六個月，長江生命科技集團有限公司（「長江生命 科技」或「公司」）錄得未經審核股東應佔虧損約港幣一億五千零八十萬元，相 較去年同期之股東應佔溢利港幣一百萬元，負差異為港幣一億五千一百八十萬元。 二零二四年上半年度與二零二五年同期比較由盈轉虧，乃歸因於公司早前 計劃增加研發投資之決定，相關款項由二零二四年之港幣七千二百九十萬元 提升至二零二五年的港幣二億三千五百三十萬元，亦即公司增加投入 港幣一億六千二百四十萬元於科研項目以加快進程。 根據公司保守之會計政策，各項研發投資於產生期間以費用入賬處理。 如二零二五年上半年度的科研開支與去年相同，期內錄得之淨溢利貢獻會較 二零二四年同期略增（增幅為港幣一千零六十萬元）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本文件的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本文件全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 董事會宣佈不派發二零二五年度中期股息（二零二四年：無） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 長江生命科技集團有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00775 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 9,611,072,400 | | 0 | | 9,611,072,400 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 9,611,072,400 | | 0 | | 9,611,072,400 | 第 2 頁 共 10 頁 v 1.1.1 ...

Core Viewpoint - Changjiang Life Science Technology (00775) issued a profit warning, expecting a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a profit of HKD 1 million in the same period of 2024, primarily due to increased R&D investments [1]. Group 1 - The company's stock dropped over 5% following the profit warning, trading at HKD 0.95 with a transaction volume of HKD 5.7489 million at the time of reporting [1]. - The expected loss marks a significant shift from the previous year's profit, indicating a strategic decision to enhance research and development efforts [1]. - Overall, the company's operations have remained stable during the reporting period and up to the date of the announcement [1].

Group 1 - The core viewpoint of the article is that Changjiang Life Science Technology (00775) issued a profit warning, leading to a decline of over 5% in its stock price, currently trading at HKD 0.95 with a transaction volume of HKD 5.7489 million [1] - The company anticipates a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a profit of HKD 1 million in the same period of 2024 [1] - The shift from profit to loss is attributed to the company's earlier decision to increase research and development investments [1] Group 2 - Overall, the company's operations have remained stable during the reporting period and up to the date of the announcement [1]

Core Viewpoint - Changjiang Life Science Technology (00775) issued a profit warning, leading to a decline of over 5% in its stock price, currently trading at HKD 0.95 with a trading volume of HKD 5.7489 million [1] Financial Performance - The company expects to report a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a shareholder profit of HKD 1 million for the same period in 2024 [1] - The shift from profit to loss is attributed to the company's earlier decision to increase research and development investments [1] Operational Stability - Overall, the company's operations have remained stable during the reporting period and up to the date of the announcement [1]

Performance Updates - 开拓药业-B (09939.HK) has completed patient enrollment for the Phase III clinical trial of KX-826 solution for androgenetic alopecia in adult males in China [2] - 李氏大药厂 (00950.HK) has received approval from the National Medical Products Administration for Socazolimab to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China [2] - 恒瑞医药 (01276.HK) has received approval for clinical trials of SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [2] - 恒瑞医药 (01276.HK) has also received approval to conduct clinical trials for HRS-5041, intended for prostate cancer treatment [2] - 深圳高速公路股份 (00548.HK) reported toll revenue of 106 million yuan for the outer ring project in June [2] - 大成生化科技 (00809.HK) has signed an EPC contract with Northeast Electric and Liaoning Electric for boiler renovation projects, with a maximum cost of 129.1 million yuan [2] - 小黄鸭德盈 (02250.HK) has signed a contract to develop an AI marketing system to diversify revenue sources [2] Buyback and Financing Activities - 威海银行 (09677.HK) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly 3 billion yuan [2] Financial Results - 香港电讯-SS (06823.HK) reported total revenue of 17.322 billion HKD for the first half, a year-on-year increase of 4%, with a net profit of 2.07 billion HKD, also up 4% [4] - 青岛银行 (03866.HK) reported operating revenue of 7.662 billion yuan for the first half, a growth of 7.5%, and a net profit of 3.065 billion yuan, up 16.05% [4] - 中国石油化工股份 (00386.HK) expects mid-term net profit to be between 20.1 billion and 21.6 billion yuan, a year-on-year decline of 39.5%-43.7% [4] - 汽车之家-S (02518.HK) reported total revenue of 3.212 billion yuan for the first half, a decrease of 7.75%, with a net profit of 772 million yuan, down 15.99% [4] - 绿茶集团 (06831.HK) issued a profit warning, expecting mid-term net profit to be between 230 million and 237 million yuan, a year-on-year increase of approximately 32%-36% [4] - 粤海置地 (00124.HK) issued a profit warning, expecting mid-term net profit to exceed 260 million HKD, turning from loss to profit [4] - 药师帮 (09885.HK) issued a profit warning, expecting mid-term net profit to exceed 70 million yuan [4] - 中国东方教育 (00667.HK) issued a profit warning, expecting mid-term net profit to grow by 45%-50% year-on-year [4] - 中核国际 (02302.HK) issued a profit warning, expecting mid-term revenue to increase to at least 585 million HKD, with net profit of at least 9.5 million HKD [4] - 大唐环境 (01272.HK) issued a profit warning, expecting mid-term net profit to decrease to between 350 million and 400 million yuan [4] - 长江生命科技 (00775.HK) issued a profit warning, expecting mid-term net loss of approximately 150 million HKD, turning from profit to loss year-on-year [4] - 延长石油国际 (00346.HK) issued a profit warning, expecting mid-term loss of approximately 27.9 million HKD [4]